This is a phase 0 study that will enable an assessment of biodistribution and estimation of
absorbed dose in humans based on data collected from five healthy volunteers, which is
typically the minimum number required by the FDA for first-in-human studies to assess
dosimetry of a new tracer. The evaluation of the brain imaging of thirty additional subjects
in the 2nd part of the study will lead to a descriptive assessment of the targeting and
pharmacokinetics of MPC6827 in the brain and between normal and diseased brain.